NEW!

More documents

Recommendations

Info

Wednesday, April 20 Integrated Neuroscience Session 1:00 p.m.–5:30 p.m. Integrated Neuroscience Session I12 S Amyloid and Beyond: From Bench to Bedside This program is offered in partnership with the Geriatric Neurology Section. Coordinators: David S. Knopman, MD, FAAN, and Liana Apostolova, MD, FAAN Program Description: Amyloid and more recently tau imaging have demonstrated excellent sensitivity and specificity for detecting amyloid and tau pathology in the human brain. In this INS we will review the latest scientific evidence regarding the basic mechanisms for amyloid toxicity, as well as the most recent advances in tau and amyloid imaging in research and clinical care. Upon Completion: Participants should be able to gain knowledge of the role of amyloid species in normal aging and AD, understand the role new imaging methods play in neurodegenerative diseases, gain knowledge of the specific imaging biomarker signatures of the major classes of neurodegenerative diseases and understand how biomarkers can be used in conjunction with clinical findings to refine the differential diagnosis. Part I 1:00 p.m.–3:30 p.m. 1:00 p.m.–1:10 p.m. Introduction Liana Apostolova, MD, FAAN, and David S. Knopman, MD, FAAN 1:10 p.m.–1:50 p.m. Invited Speaker Amyloid Oligomers vs. Fibrillar Amyloid in Aging and Alzheimer’s Disease Karen Hsiao Ashe, MD, PhD, Minneapolis, MN 1:50 p.m.–1:55 p.m. I12.001 FERMT2 Is Associated with Brain Amyloidosis in Cognitively Normal and Mild Cognitive Impairment Subjects —Naira Goukasian, Triet Do, Jonathan Grotts, Dan Silverman, David Elashoff, Liana Apostolova 1:55 p.m.–2:00 p.m. I12.002 Multimorbidity and Neuroimaging Biomarkers Among Cognitively Normal Persons —Maria Vassilaki, Jeremiah Aakre, Michelle Mielke, Yonas Geda, Walter Kremers, Rabe Alhurani, Mary Machulda, David Knopman, Ronald Petersen, Val Lowe, Clifford Jack, Rosebud Roberts 2:00 p.m.–2:05 p.m. I12.003 Differences in 11C-PIB-PET Imaging Patterns Between Alzheimer’s Disease Patients with and Without Cerebral Cortical/Subcortical Microbleeds —Yuichi Hayashi, Jun Shinoda, Nobuaki Yoshikura, Masahiro Waza, Hiroshi Nishida, Yoshitaka Asano, Akio Kimura, Takashi Inuzuka 2:05 p.m.–2:20 p.m. Audience Q&A 2:20 p.m.–3:00 p.m. Invited Speaker Current State of Tau PET Imaging Bradford Dickerson, MD, Charlestown, MA 3:00 p.m.–3:05 p.m. I12.004 Literature Review of Genetic Disorders with Tau Pathology —Pawel Tacik, Zbigniew Wszolek, Monica Sanchez-Contreras, Rosa Rademakers, Dennis Dickson 3:05 p.m.–3:10 p.m. I12.005 Imaging Tau Pathology In Vivo in AD and FTLD Spectrum Tauopathies with [18F] AV1451 PET —Bradford Dickerson, Sara Makaretz, Christina Caso, Michael Stepanovic, Megan Quimby, Chenjie Xia, Scott McGinnis, Matthew Frosch, Keith Johnson 3:10 p.m.–3:15 p.m. I12.006 Amyloid-β and Hyperphosphorylated Tau Synergy Drives Metabolic Decline in Preclinical Alzheimer’s Disease —Tharick Pascoal, Sulantha Mathotaarachchi, Andrea Benedet, Tom Beaudry, Serge Gauthier, Pedro Rosa Neto 3:15 p.m.–3:30 p.m. Audience Q&A Guided Poster Rounds I12.001 FERMT2 Is Associated with Brain Amyloidosis in Cognitively Normal and Mild Cognitive Impairment Subjects —Naira Goukasian, Triet Do, Jonathan Grotts, Dan Silverman, David Elashoff, Liana Apostolova I12.002 Multimorbidity and Neuroimaging Biomarkers Among Cognitively Normal Persons —Maria Vassilaki, Jeremiah Aakre, Michelle Mielke, Yonas Geda, Walter Kremers, Rabe Alhurani, Mary Machulda, David Knopman, Ronald Petersen, Val Lowe, Clifford Jack, Rosebud Roberts 3:30 p.m.–4:15 p.m. I12.003 Differences in 11C-PIB- PET Imaging Patterns Between Alzheimer’s Disease Patients with and Without Cerebral Cortical/Subcortical Microbleeds —Yuichi Hayashi, Jun Shinoda, Nobuaki Yoshikura, Masahiro Waza, Hiroshi Nishida, Yoshitaka Asano, Akio Kimura, Takashi Inuzuka I12.004 Literature Review of Genetic Disorders with Tau Pathology —Pawel Tacik, Zbigniew Wszolek, Monica Sanchez- Contreras, Rosa Rademakers, Dennis Dickson I12.005 Imaging Tau Pathology In Vivo in AD and FTLD Spectrum Tauopathies with [18F] AV1451 PET —Bradford Dickerson, Sara Makaretz, Christina Caso, Michael Stepanovic, Megan Quimby, Chenjie Xia, Scott McGinnis, Matthew Frosch, Keith Johnson I12.006 Amyloid-β and Hyperphosphorylated Tau Synergy Drives Metabolic Decline in Preclinical Alzheimer’s Disease —Tharick Pascoal, Sulantha Mathotaarachchi, Andrea Benedet, Tom Beaudry, Serge Gauthier, Pedro Rosa Neto I12.007 Prevalence of Amyloid Pathology in Primary Progressive Aphasia Variants: A Systematic Review and Meta- Analysis —David Bergeron, Robert Laforce, Rik Ossenkoppele I12.008 Rapidly Progressive Alzheimer’s Disease in Two Distinct Autopsy Cohorts —Jagan Pillai, Brian Appleby, Jiri Safar, James Leverenz I12.009 Biomarker Confirmed Alzheimer’s Disease Presenting As Amnestic, Aphasic, and Visual Variants: Hippocampal Volume Comparison —Alissa Butts, Mary Machulda, Joseph Duffy, Edythe Strand, Daniel Drubach, Scott Przybelski, Ronald Petersen, Clifford Jack, Val Lowe, Keith Josephs, Jennifer Whitwell Part II I12.010 Cascading Network Failure Across the Alzheimer’s Disease Spectrum —David Jones, David Knopman, Jeffery Gunter, Jonathan Graff-Radford, Prashanthi Vemuri, Bradley Boeve, Ronald Petersen, Michael Weiner, Clifford Jack I12.011 Behavioral Correlates of Cognitive Decline in Normal Aging and Prodromal Alzheimer’s Disease —Naira Goukasian, Triet Do, Jonathan Grotts, John Ringman, David Elashoff, Liana Apostolova I12.012 Effect of Brain Amyloidosis on the Emergence of Neuropsychiatric Behaviors in MCI over Time —Liana Apostolova, Naira Goukasian, Triet Do, Jonathan Grotts, John Ringman, David Elashoff I12.013 Sensitivity, Specificity and Reliability of Three Pathological Criteria for Alzheimer’s Disease —Alexis Steinberg, Oscar Lopez, Julia Kofler, James Becker, Robert Sweet, Sarah Berman, Eric McDade, Eric Rodriguez, William Klunk 4:15 p.m.–5:30 p.m. 4:15 p.m.–4:55 p.m. Invited Speaker PET Imaging of Alzheimer’s Disease Variants and non-Alzheimer’s Disease Dementias Robert Laforce Jr., MD, PhD, Quebec, Canada 4:55 p.m.–5:00 p.m. I12.007 Prevalence of Amyloid Pathology in Primary Progressive Aphasia Variants: A Systematic Review and Meta-Analysis —David Bergeron, Robert Laforce, Rik Ossenkoppele 5:00 p.m.–5:05 p.m. I12.008 Rapidly Progressive Alzheimer’s Disease in Two Distinct Autopsy Cohorts —Jagan Pillai, Brian Appleby, Jiri Safar, James Leverenz 5:05 p.m.–5:15 p.m. Audience Q&A 5:15 p.m.–5:30 p.m. Conclusion 128 2016 AAN Annual Meeting Abstract Listing
Scientific Platform Sessions Meeting Schedule 3:30 p.m.–5:30 p.m. Scientific Platform Sessions S42: Stroke Mechanism and Modifiers 3:30 p.m. S42.001 Can CREST Procedural Results Be Reproduced in General Practice in Post CREST Era? Analysis of National Surgical Quality Improvement Program (NSQIP) Registry —Vishal Jani, Aiman Zafar, Mohammad Afzal, Adnan Qureshi 3:45 p.m. S42.002 Prevalence, Risk Factors, and Clinical Significance of Asymptomatic Extracranial Vertebral Artery Disease in Patients with Symptomatic Internal Carotid Artery Stenosis: Analysis of Stent-Protected Angioplasty Versus Carotid Endarterectomy (SPACE) Trial —Adnan Qureshi, Saqib Chaudhry, Olav Jansen, Hans-Henning Eckstein, Peter Ringleb 4:00 p.m. S42.003 Incidence of Atrial Fibrillation Within One Year of Cryptogenic Stroke Among a Large, Real-World Population with Insertable Cardiac Monitors —John Rogers, Allan Nichols, Mark Richards, Scott Ferreira, Shantanu Sarkar, Jodi Koehler, Eduardo Warman, Paul Ziegler 4:15 p.m. S42.004 Elevated FVIII Predicts Subsequent Acute Ischemic Stroke in Patients with Transient Ischemic Attack —Eleanor Semmes, Dominique Monlezun, Jr, Alyana Samai, Sheryl Martin-Schild 4:30 p.m. S42.005 Household Secondhand Smoke Exposure Confers Higher Stroke Risk and Poorer Stroke Prognosis —Michelle Lin, Bruce Ovbiagele, Daniela Markovic, Amy Towfighi 4:45 p.m. S42.006 Placental Pathology in Neonatal Stroke: A Retrospective Case-Control Study —Miya Bernson-Leung, Theonia Boyd, Amy Danehy, Emily Meserve, Michael Rivkin 5:00 p.m. S42.007 Intra-Arterial Mesenchymal Stem Cells in a Large Animal Endovascular Canine Stroke Model: Findings on Serial Diffusion Tensor Imaging —Luis Guada, Pradip Pattany, Kevin Ramdas, Dileep Yavagal 5:15 p.m. S42.008 Incidental Cerebral Microbleeds and Cerebral Hypoperfusion in Cognitively Normal Elderly Individuals —Nicholas Gregg, Davneet Minhas, Albert Kim, Edip Gurol, Oscar Lopez, Howard Aizenstein, Julie Price, Chester Mathis, Jeffrey James, Beth Snitz, Ann Cohen, M. Kamboh, Lisa Weissfeld, Erica Tamburo, William Klunk S43: Motor Neuron Disease, Outcome, and Assessment to Therapy in Neuromuscular Disorders 3:30 p.m. Presentation of the Sheila Essey Award: An Award for ALS Research Presented by the American Academy of Neurology and the ALS Association and supported through the philanthropy of the Essey Family Fund and the ALS Association. Recipient: Ammar Al-Chalabi, MD ChB, PhD London, United Kingdom 4:00 p.m. S43.003 Pilot Placebo-Controlled Study of Early Noninvasive Ventilation for ALS —Teresa Jacobs, Jonggyu Baek, Devin Brown, Erin Migda, Timothy Funckes, Gruis Kirsten 4:15 p.m. S43.004 “Dominant-Negative Effect” Mechanism in OPTNE478G-Linked Amyotrophic Lateral Sclerosis —Yong Shi, Faisal Fecto, Y. Taylan Esengul, Teepu Siddique, Han-Xiang Deng 4:30 p.m. S43.005 Functional Outcomes in Hereditary Spastic Paraplegia: A Prospective Cohort Study —Nicolas Chrestian, Nicolas Dupre, Jean-Denis Brisson, Ziv Gan-Or, Anna Szuto, Shiyi Chen, Anil Venkitachalam, Jodi Warman Chardon, Sohnee Ahmed, Setareh Ashtiani, Heather MacDonald, Pierre Provencher, Kym Boycott, Dimitri Stravropoulos, Patrick Dion, Peter Ray, Oksana Suchowersky, Guy Rouleau, Grace Yoon 4:45 p.m. S43.006 Biomarker Development for C9ORF72 Antisense Therapy Using IPS Neurons —Lindsey Hayes, Chris Donnelly, Tania Gendron, Leonard Petrucelli, Jeffrey Rothstein 5:00 p.m. S43.007 Can Pyrimethamine Lower CSF SOD1 Levels in Familial ALS? Results from a Multicenter Phase Ib Trial —Dale Lange, Rahul Remanan, Mona Shahbazi, Vincenzo Silani, Albert Ludolph, Senda Ajroud-Driss, Stanley Appel, Lindsay Kaplan, Kara Fields, Stefan Marklund, Peter Andersen 5:15 p.m. S43.008 Disease Burden and Functional Outcomes in Congenital Myotonic Dystrophy: A Cross-Sectional Study — Nicholas Johnson, Man Hung, Melissa Dixon, Deanna DiBella, Evan Pucillo, Kiera Berggren, Heather Hayes, Wei Chen, Russell Butterfield, Chad Heatwole, Craig Campbell 3:30 p.m.–5:30 p.m. S42 Stroke Mechanism and Modifiers S43 Motor Neuron Disease, Outcome, and Assessment to Therapy in Neuromuscular Disorders C190 Therapy in Neurology IV Director: Steven L. Lewis, MD, FAAN, Chicago, IL C191 Clinical Epilepsy III Director: Page B. Pennell, MD, Boston, MA C192 Sports Concussion and Other Mild Concussive Injuries II Director: David W. Dodick, MD, Phoenix, AZ C193 Genomic Neurology Workshop: Developing Practical Knowledge of Tools and Concepts Through Case Studies II Director: Jeffery M. Vance, MD, PhD, Miami, FL C194 Multiple Sclerosis Therapy: Disease-modifying Treatment II Director: Bruce A. C. Cree, MD, PhD, MCR, San Francisco, CA C195 The Neurology of Social Behavior Director: Bradford Dickerson, MD, Charlestown, MA C196 Neuro-otology II Director: Terry D. Fife, MD, FAAN, Phoenix, AZ C197 Approach to the Shaky Patient Director: Vicki Shanker, MD, New York, NY C198 Clinical EMG III Director: Mark B. Bromberg, MD, PhD, FAAN, Salt Lake City, UT C199 Navigating Primary Brain Tumors for the Neurologist II Director: Erin M. Dunbar, MD, Atlanta, GA C200 Neurologic Case Studies in Pregnancy II Director: Mary Angela O’Neal, MD, Boston, MA C201 Neurocysticercosis and Globalization Director: Jorge G. Burneo, MD, MSPH, FAAN, London, ON Invited Science: Multiple Sclerosis . . . . . . . . . 127 6:00 p.m.–7:30 p.m. Emerging Science Session Wed· April 20 Fast and easy registration · AAN.com/view/AM16 129
Page 1 and 2:
NEW! Dates • Format • Value SCI
Page 3 and 4:
See the value! 2015 Meeting Price 2
Page 5 and 6:
What’s Inside Table of Contents I
Page 7 and 8:
Meeting! INTRODUCTION See You in Va
Page 9 and 10:
Additional Information INTRODUCTION
Page 11 and 12:
OVERVIEWS Mon April 18 Tue April 19
Page 13 and 14:
Schedule Planning Forms Use the con
Page 15 and 16:
My Friday $ A registration fee is r
Page 17 and 18:
Hot Topics Plenary Session Friday,
Page 19 and 20:
$ A registration fee is required L
Page 21 and 22:
Meeting Schedule 6:30 a.m.-8:30 a.m
Page 23 and 24:
Poster Session Schedule and Floorpl
Page 25 and 26:
Meeting Schedule P1.029 Efficacy an
Page 27 and 28:
Presenters Stand by Posters 5:30 p.
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
New Faculty and Trainee Reception!
Page 37 and 38:
Meeting Schedule 11:30 a.m.-6:30 p.
Page 39 and 40:
Saturday, April 16 1:00 p.m.-3:00 p
Page 41 and 42:
Meeting Schedule 1:00 p.m.-5:30 p.m
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Meeting Schedule 6:30 a.m.-7:15 a.m
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Sunday, April 17 Scientific Platfor
Page 61 and 62:
Meeting Schedule 1:00 p.m.-5:00 p.m
Page 63 and 64:
I5 1:00 p.m.-5:30 p.m. Integrated N
Page 65 and 66:
Opening Party Experience New Ways t
Page 67 and 68:
Page 69 and 70:
Don’t Forget to Visit the Exhibit
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80: P3.391 The Quix Test: A 30 Second T
Page 81 and 82: Annual Meeting App Now Available Th
Page 83 and 84: Meeting Schedule 9:00 a.m.-11:30 a.
Page 85 and 86: Meeting Schedule 1:00 p.m.-5:30 p.m
Page 87 and 88: I8 1:00 p.m.-5:30 p.m. Integrated N
Page 89 and 90: Industry Therapeutic Updates Indust
Page 91 and 92: $ A registration fee is required L
Page 93 and 94: Meeting Schedule 6:30 a.m.-8:30 a.m
Page 95 and 96: Presenters Stand by Posters 5:30 p.
Page 103 and 104: Frontiers in Neuroscience Plenary S
Page 125 and 126: Clinical Trials Plenary Session Wed
Page 129: Meeting Schedule 1:00 p.m.-5:30 p.m
Page 133 and 134: My Thursday $ A registration fee is
Page 145 and 146: Neurology Year in Review Plenary Se
Page 149 and 150: 1:00 p.m.-5:30 p.m. Integrated Neur
Page 151 and 152: New Date and Time: CLOSING PARTY HA
Page 159 and 160: Association of Indian Neurologists
Page 161 and 162: Potamkin Prize for Research in Pick
Page 163 and 164: Cool An AAN initiative to help buil
Page 165 and 166: Closing Party Happy Hour Thursday,
Page 167 and 168: Annual Meeting Attendee Pricing: Go
Page 169 and 170: Disclaimers/Disclosures Disclaimer
Page 171 and 172: Hotel Reservations Why Book a Hotel
Page 173 and 174: Sitka Sq Abbott St Ontario St Ontar
Page 175 and 176: Luggage Restrictions for carry-on b
Page 177 and 178: 68 th Annual Meeting Exhibitors as
Page 179 and 180: 68 th Annual Meeting Planning Meeti
Page 181 and 182:
Jonathan S. Katz, MD Jori Fleisher,
Page 183 and 184:
AAN Leadership University courses a
show all

NEW!

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?